Table S1 Features of patients who received chemotherapy and survived 1 year with odds ratios for 1 year survival in all stages

Factor	Number surviving 1 year (n=695)	surviving 1 year from those receiving		95% CI	Adjusted OR 1-year survival	95% CI	P value (LR test)	
Sex								
Female	404	45.3	1		1			
Male	291	33.5	0.61	0.50-0.73	0.61	0.48-0.76	<0.01	
Age group								
<60	150	45.2	0.79	0.62-1.01	1	0.74-1.35		
60-79	498	39.4	1		1			
≥80	47	28.3	0.48	0.32-0.72	0.74	0.45-1.21	0.53 <sup>¥</sup>	
Townsend quintile								
Least deprived- 1	97	44.7	1		1			
2	108	37.2	0.73	0.51-1.05	0.8	0.52-1.22		
3	142	39.1	0.79	0.57-1.12	1.02	0.68-1.53		
4	185	41.3	0.87	0.63-1.21	1.01	0.68-1.50		
Most deprived- 5	163	36.8	0.72	0.52-1.00	0.88	0.59-1.31	0.61	
Performance status								
0	196	54.9	1		1	1		
1	307	44.2	0.65	0.50-0.84	0.71	0.53-0.97		
2	119	28.9	0.33	0.25-0.45	0.44	0.31-0.63		
3	24	16.7	0.16	0.10-0.27	0.29	0.17-0.51		
4	1	7.7	0.07	0.01-0.53	0.05	0.00-0.63		
Missing	48	34.3	0.43	0.29-0.64	0.46	0.29-0.75	<0.01	
Charlson comorbidity index								
0	240	45.4	1		1			
1	193	52.6	1.34	1.02-1.74	1.42	1.03–1.96		
2-3	128	37	0.71	0.54-0.93	0.84	0.60–1.17		
≥4	134	25.8	0.42	0.32-0.54	0.75	0.55–1.01	<0.01	
Stage								
Limited	381	60.7	1		1			
Extensive	286	26.2	0.23	0.19-0.29	0.3	0.23-0.39		
Missing	28	66.7	1.3	0.67–2.51	1.54	0.72–3.28	<0.01	
Chemotherapy								
Carboplatin+ etoposide	530	38.4	1		1			
Cisplatin + etoposide	133	67.9	3.39	2.46–4.66	1.48	0.99–2.21		
CAV	1	20	0.4	0.04–3.60	0.64	0.05-8.59		
Other	11	34.4	0.84	0.40–1.76	1.4	0.61–3.24		
Single platinum	14	11.1	0.2	0.11–0.35	0.42	0.23-0.79		
Missing	6	27.3	0.6	0.23–1.55	1.06	0.33–3.41	0.02	
Chemotherapy cycles received		27.5	0.0	0.20-1.55	1.00	0.55-5.41	0.02	
More than planned (mean 5 cycles)	16	53.3	0.89	0.41–1.93	0.9	0.36–2.27		
Less than planned (mean 3 cycles)	275	32	0.37	0.27-0.50	0.47	0.32-0.68		
4 planned and received	115	56.1	1		1			
6 planned and received	203	52.5	0.86	0.61–1.21	1.22	0.82-1.83		
Received planned amount excluding 4 & 6 cycles (mean 2 cycles)	27	28.4	0.31	0.18-0.52	0.36	0.18–0.72		
Missing planned cycles	59	32.1	0.37	0.24-0.56	0.45	0.28-0.74	<0.01	
Received radiotherapy								
Did not receive radiotherapy	269	27.8	1		1			
Radical (≥40 Gy)	233	77.4	8.91	6.58–12.09	2.94	2.04-4.25		
Palliative (<40 Gy)	193	39.3	1.69	1.34–2.12	1.43	1.10–1.87	<0.01	
Received PCI		-			-			
No	469	33.6	1		1			
Yes	226	61.9	3.21	2.53-4.08	2.08	1.54–2.79	<0.01	

<sup>¥:</sup> LR test for trend. Adjusted OR for all other factors in table.

Table S2 Sensitivity analysis of 1-year survival with different radiotherapy thresholds for limited stage SCLC

Radiotherapy received	Number surviving 1 year	Proportion surviving 1 year from all who received chemotherapy	OR 1-year survival	95% CI	Adjusted OR 1-year survival	95%CI	P value likelihood ratio rest
Received radiotherapy							
Did not receive radiotherapy	119	44.2	1	-	1	-	<0.01
Radical (≥40 Gy)	197	81.4	5.52	3.69-8.26	3.32	2.07-5.31	
Palliative (<40 Gy)	65	55.6	1.58	1.02-2.44	1.53	0.94-2.49	
Received radiotherapy							
Did not receive radiotherapy	381	44.2	1	-	1	-	<0.01
Radical (≥30 Gy)	236	77.6	4.37	3.15–6.28	2.83	1.84-4.34	
Palliative (<30 Gy)	26	47.3	1.13	0.63-2.02	1.31	0.69–2.47	

Odds ratios are adjusted for sex, age, social deprivation, PS, comorbidity, receipt of PCI, chemotherapy regimen and cycles.

Table S3 Characteristics of individuals receiving chemotherapy who had limited stage

Factor —	Receive	d 4 cycles	Receiv	ed 6 cycles	P value for differences between	
racioi —	Number	Percentage	Number	Percentage	treatment groups (chi²)	
Sex						
Male	40	44	57	48	0.53	
Female	51	56	61	52		
Age (median & IQR)	69 (	60-75)	67	(60-73)	0.60 (t test)	
Performance status						
0	29	32	30	25	0.57	
1	42	46	52	44		
2	13	14	20	17		
3	1	1	4	3		
Missing	6	7	12	10		
Charlson comorbidity score						
0	35	38	30	25	0.12	
1	26	29	50	42		
2-3	21	23	24	20		
4	9	10	14	12		
Socioeconomic status						
1-Least deprived	14	15	18	15	0.89	
2	15	16	20	17		
3	16	18	21	18		
4	25	27	26	22		
5-Most deprived	21	23	33	28		

Table S4 Characteristics of individuals receiving chemotherapy who had extensive stage

Factor	Receive	d 4 cycles	Receiv	red 6 cycles	P value for differences between		
Factor -	Number	Percentage	Number	Percentage	treatment groups (chi²)		
Sex							
Male	49	45	137	52	0.21		
Female	59	55	124	48			
Age (median + IQR)	68 (	62-74)	68	(61-73)	0.24 (t test)		
Performance status							
0	12	11	55	21	0.03		
1	41	38	105	40			
2	38	35	61	23			
3	10	9	14	5			
Missing	7	6	26	10			
Charlson comorbidity index							
0	38	35	87	33	0.94		
1	20	19	46	18			
2-3	16	15	37	14			
≥4	34	31	91	35			
Socioeconomic status							
1-Least deprived	17	16	30	11	0.624		
2	21	19	47	18			
3	24	22	59	23			
4	21	19	68	26			
5-Most deprived	25	23	57	22			

Table S5 Characteristics of individuals receiving PCI who had extensive stage

Factors	Did not r	eceive PCI	Rece	eived PCI	P values for differences between	
Factors -	Number	Percentage	Number	Percentage	treatment groups (chi²)	
Sex						
Male	455	52	107	50	0.68	
Female	423	48	106	50		
Age (median & IQR)	69 (	62-75)	64	(59-70)	<0.01 (t test)	
Performance status						
0	143	16	49	23	<0.01	
1	320	36	101	47		
2	238	27	39	18		
3	101	12	13	6		
Missing	76	9	11	5		
Charlson score						
0	250	28	75	35	0.08	
1	147	17	38	18		
2-3	152	17	24	11		
≥4	329	37	76	36		
Socioeconomic status						
Least deprived-1	95	11	26	12	0.95	
2	147	17	35	16		
3	190	22	49	23		
4	218	25	49	23		
Most deprived-5	228	26	54	25		

Table S6 Characteristics of individuals receiving radiotherapy who had extensive stage

Factors	Received palliative dose (<40 Gy)		Received consolidative dose (≥40 Gy)		P value for difference between treatment groups	Received palliative dose (<30 Gy)		Received consolidative dose (≥30 Gy)		P value for difference between treatment groups (chi <sup>2</sup> )
	Number	%	Number	%	(chi²)	Number	%	Number	%	groups (crii )
Sex										
Male	204	55	18	44	0.16	104	65	118	47	<0.01
Female	164	45	23	56		55	35	132	53	
Age (median and IQR)	67 (61	-72)	65 (60	)-73)	0.84 (t test)	68 (62	-74)	65 (60	)-72)	0.02 (t test)
Performance :	status									
0	78	21	10	24	0.15	24	15	64	26	0.07
1	154	42	19	46		71	45	102	41	
2	78	21	5	12		32	20	51	20	
3	33	9	1	2		18	11	16	6	
Missing	25	7	6	15		14	9	17	7	
Charlson com	orbidity scor	е								
0	129	35	13	32	<0.01	52	33	90	36	< 0.03
1	61	17	15	37		25	16	51	20	
2-3	44	12	9	22		15	9	38	15	
≥4	134	36	4	10		67	42	71	28	
Socioeconom	ic status									
Least deprived-1	37	10	4	10	0.28	15	9	26	10	1.00
2	58	16	6	15		25	16	39	16	
3	72	20	13	32		35	22	50	20	
4	99	27	12	29		44	28	67	27	
Most deprived-5	102	28	6	15		40	25	68	27	